Quantcast

Latest Chelsea Therapeutics Stories

2008-11-13 09:00:37

CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical program for CH-4051, the second drug candidate from its portfolio of orally available, non-metabolized antifolates engineered to provide potent anti-inflammatory activity without the liver and kidney toxicities or tolerability related side effects associated with chronic methotrexate (MTX)...

2008-11-12 09:00:46

CHARLOTTE, N.C., Nov. 12, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will be hosting its 2008 analyst and institutional investor day from 9:30 AM to 12:00 PM on Friday, November 21, 2008 at The Grand Hyatt Hotel in New York City. The event will be moderated by Dr. Simon Pedder, President and CEO of Chelsea Therapeutics and will include an in-depth discussion of the Company's product pipeline, growth opportunities and development strategy including...

2008-11-03 09:00:40

* Responders Demonstrated Mean Reduction in Symptomatic Score of 4.6 Units and Increase of 27mmHg in Standing Systolic Blood Pressure CHARLOTTE, N.C., Nov. 3, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that data from the open-label titration portion of Chelsea's Phase III trial demonstrated patients treated with Droxidopa, a synthetic precursor to norepinephrine, showed a robust reduction in the severity of symptoms associated with...

2008-10-28 09:00:07

CHARLOTTE, N.C., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a novel metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. "Having recently received a favorable recommendation from an independent data safety monitoring board and now having completed...

2008-10-21 09:00:54

CHARLOTTE, N.C., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that an independent Data Safety Monitoring Board (DSMB) recently met to review patient safety and efficacy data for Chelsea's Phase II trial of CH-1504 in rheumatoid arthritis (RA) and recommended that each arm of the study continue as planned. "We are very encouraged that this DSMB review provided us with a recommendation to continue each arm of the study as planned,"...

2008-10-20 09:00:42

CHARLOTTE, N.C., Oct. 20, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Oppenheimer 19th Annual Healthcare Conference at 10:40 AM on Tuesday, November 4, 2008 at the Waldorf-Astoria Hotel in New York City. Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones. Dr. Pedder's presentation will be webcast...

2008-09-16 09:00:53

CHARLOTTE, N.C., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the UBS Global Life Sciences Conference at 11:00 AM on Monday, September 22, 2008 at The Grand Hyatt Hotel in New York City. Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones. Dr. Pedder's presentation will be webcast live and...

2008-09-02 09:00:07

CHARLOTTE, N.C., Sept. 2, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has initiated patient dosing in Study 301, the second of two pivotal Phase III trials designed to demonstrate efficacy and support U.S. marketing approval of Droxidopa in neurogenic orthostatic hypotension (NOH). Study 301 is a multinational, randomized, placebo-controlled, induction-design Phase III trial evaluating up to 118 patients. The trial is approximately 4...

2008-08-27 09:01:27

Chelsea Therapeutics has announced that the FDA has granted fast track designation to Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension. In addition to fast track designation, the FDA has granted Droxidopa orphan drug status for the treatment of symptomatic neurogenic orthostatic hypotension and subsequently awarded Chelsea a special protocol assessment (SPA) for the second of its pivotal studies in this program. An SPA provides a binding agreement that the...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.